Oxford BioMedica has collaborated with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial Innovations for the development of a long-term therapy to treat patients with cystic fibrosis.
07 Aug 2018
16 Apr 2018
Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain programs.
07 Nov 2016
Biopharmaceutical firm Onxeo has announced encouraging results from a series of preclinical studies evaluating Livatag interest for pancreatic cancer.